A Phase 3 interventional study of insulin aspart and inhaled human insulin in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Terminated at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-05.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing Insulin, Regular, Human in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus.
Among the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, this one is the 38th largest by enrollment, is one of 9 that started in 2007, is one of 18 in phase 3, and was the 14th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus are open now, in 1 country. Recruiting first, the newest first:
Mannkind Corporation · Sites in United States
Ages 6–17
Columbia University · Sites in United States
Ages 18–65
By country, each count listing its studies:
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4 · Phase 3 18 · Phase 4 9
First in 1989; this study’s year is marked. 9 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 60 across the 41 interventional studies. Of the 38 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 41 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
642 studies in Diabetes Mellitus by Novo Nordisk A/S: 2 open now, 3 under way, 1 of them phase 3. Of 636 finished, 163 (26%) have results posted.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 486th largest by enrollment of the 494 interventional ones that give a count, is one of 42 that started in 2007, is one of 182 in phase 3, and was the 71st registered.
Novo Nordisk A/S’s Diabetes Mellitus studies by the year they started, since 1989.
1 of the studies testing Insulin, Regular, Human in Diabetes Mellitus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07224321Mannkind CorporationINHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 642 in Diabetes Mellitus:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe, Asia, Oceania and the United States of America (USA).
This is a one-year clinical trial to compare the safety of inhaled preprandial human insulin to subcutaneous insulin aspart in subjects with type 1 or 2 diabetes and asthma.
The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: inhaled human insulin
Drug: insulin aspart
Treat-to-target dose titration scheme, injection s.c.
Also known as: NovoRapid®, NovoLog®
Treat-to-target dose titration scheme, inhalation.
Changes in lung function, chest X-rays, or asthma exacerbation frequency
Time frame: after 52 weeks of treatment
Diabetes control measured by change in HbA1c
Time frame: from baseline to end of treatment
Laboratory assessments (biochemistry, insulin antibodies, blood count)
Time frame: from baseline to end of treatment
Preprandial insulin doses
Time frame: for the duration of the trial
Ran from Aug 2007 to primary completion in Feb 2008, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human